Trial Profile

Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxapram (Primary)
Indications Atrial fibrillation
Focus Therapeutic Use
Acronyms Doctos

Most Recent Events

30 Dec 2023 Status changed from recruiting to discontinued.
18 Apr 2020 Planned number of patients changed from 50 to 40.
26 Dec 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com